Predicting Phenotypic Severity of Uncertain Gene Variants in the RET Proto-Oncogene

被引:24
|
作者
Crockett, David K. [1 ,2 ]
Piccolo, Stephen R. [1 ]
Ridge, Perry G. [2 ]
Margraf, Rebecca L. [2 ]
Lyon, Elaine [2 ]
Williams, Marc S. [1 ,3 ]
Mitchell, Joyce A. [1 ]
机构
[1] Univ Utah Sch Med, Salt Lake City, UT 84132 USA
[2] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA
[3] Intermt Healthcare Clin Genet Inst, Salt Lake City, UT USA
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
ENDOCRINE NEOPLASIA TYPE-2; MEDULLARY-THYROID CANCER; AMINO-ACID SUBSTITUTIONS; AFFECT PROTEIN FUNCTION; CLINICAL GENETICS; MUTATIONS; DISEASE; DATABASE; SIFT;
D O I
10.1371/journal.pone.0018380
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although reported gene variants in the RET oncogene have been directly associated with multiple endocrine neoplasia type 2 and hereditary medullary thyroid carcinoma, other mutations are classified as variants of uncertain significance (VUS) until the associated clinical phenotype is made clear. Currently, some 46 non-synonymous VUS entries exist in curated archives. In the absence of a gold standard method for predicting phenotype outcomes, this follow up study applies feature selected amino acid physical and chemical properties feeding a Bayes classifier to predict disease association of uncertain gene variants into categories of benign and pathogenic. Algorithm performance and VUS predictions were compared to established phylogenetic based mutation prediction algorithms. Curated outcomes and unpublished RET gene variants with known disease association were used to benchmark predictor performance. Reliable classification of RET uncertain gene variants will augment current clinical information of RET mutations and assist in improving prediction algorithms as knowledge increases.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Distribution of RET proto-oncogene variants in children with appendicitis
    Schultz, Jurek
    Freibothe, Ines
    Haase, Michael
    Glatte, Patrick
    Barreton, Gustavo
    Ziegler, Andreas
    Goergens, Heike
    Fitze, Guido
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2022, 10 (02):
  • [2] Conservation of RET proto-oncogene splicing variants and implications for RET isoform function
    Carter, MT
    Yome, JL
    Marcil, MN
    Martin, CA
    Vanhorne, JB
    Mulligan, LM
    CYTOGENETICS AND CELL GENETICS, 2001, 95 (3-4): : 169 - 176
  • [3] RET proto-oncogene and thyroid cancer
    Komminoth, P
    ENDOCRINE PATHOLOGY, 1997, 8 (03) : 235 - 239
  • [4] RET proto-oncogene and thyroid cancer
    Paul Komminoth
    Endocrine Pathology, 1997, 8 : 235 - 239
  • [5] The RET proto-oncogene in sporadic pheochromocytomas
    Takaya, K
    Yoshimasa, T
    Arai, H
    Tamura, N
    Miyamoto, Y
    Itoh, H
    Nakao, K
    INTERNAL MEDICINE, 1996, 35 (06) : 449 - 452
  • [6] The RET proto-oncogene in human cancers
    Jhiang, SM
    ONCOGENE, 2000, 19 (49) : 5590 - 5597
  • [7] The RET proto-oncogene in human cancers
    Sissy M Jhiang
    Oncogene, 2000, 19 : 5590 - 5597
  • [8] Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases
    Ahmed, SA
    Snow-Bailey, K
    Highsmith, WE
    Sun, WM
    Fenwick, RG
    Mao, R
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (02): : 283 - 288
  • [9] Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma
    Magalhaes, PKR
    de Castro, M
    Elias, LLK
    Soares, EG
    Maciel, LMZ
    THYROID, 2004, 14 (10) : 848 - 852
  • [10] Three novel mutations in the RET proto-oncogene
    Kalinin, VN
    Amosenko, FA
    Shabanov, MA
    Lubchenko, LN
    Hosch, SB
    Garkavtseva, RF
    Izbicki, JR
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (10): : 609 - 612